Dural Arteriovenous Fistulas Treatment Market Research Report- Forecast till 2030

Dural Arteriovenous Fistulas Treatment Market Information: By Type (Type I, Type II, Type III), Treatment (Surgery, Stereotactic Radiosurgery, Embolization), End User (Hospitals & Clinics, Ambulatory Surgical Centers) - Forecast till 2030

ID: MRFR/Pharma/3170-HCR | December 2022 | Region: Global | 95 Pages         

Dural Arteriovenous Fistulas Treatment Market Speak to Analyst Request a Free Sample

Dural Arteriovenous Fistulas Treatment Market Scenario


The dural arteriovenous fistulas treatment market is expected to grow at a CAGR of 6.60% during the forecast period 2022-2030.

Dural arteriovenous fistulas (DAVF) is caused by abnormal connections between arteries and veins in a protective membrane on the outer layer of the brain and spine; it is a rare disease. These abnormal blood vessels divert blood from the normal paths. If the volume of diverted blood flow is large, tissue downstream may not receive an adequate blood and oxygen supply. The symptoms vary, depending on the location of fistulae. Headaches are among the most common symptoms with all types of DAVFs. Other symptoms include visual problems, ringing in ears, heart strokes, and others.


Increasing prevalence of brain injury and neurological disorders, increasing investment in biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the dural arteriovenous fistulas treatment market. Moreover, favorable reimbursement policies, increased applications, and significant investments in the development of advance technologies for the treatment methods likely to fuel the dural arteriovenous fistulas treatment market growth during the forecast period 2017-2023.


As per the Centers for Disease Control and Prevention in 2014, about 2.8 million TBI-related Emergency Department (ED) visits, hospitalizations, and deaths occurred in the United States. TBI (traumatic brain injury) contributed to the deaths of nearly 50,000 people. It was diagnosed in over 282,000 hospitalized cases and over 2.5 million ED visits.  These consisted of TBI alone or TBI in combination with other injuries. Adults aged over 75 years have the highest rates of TBI-related hospitalization and deaths.


According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of gastrointestinal disorders, or cancers, and is expected to increase further over the coming years.


However, higher cost of these treatment procedure may hamper the dural arteriovenous fistulas treatment market growth during the corresponding period.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities


Figure: Global Dural Arteriovenous Fistulae Treatment Market, by Region Market Share, 2016 (%) Dural Arteriovenous Fistulas Treatment Market

Sources: Annual reports, Press release, White paper, Company presentation


Segmentations


The dural arteriovenous fistulae treatment market is segmented on the basis of type, treatment, and end user.


On the basis of type, the dural arteriovenous fistulas treatment market is segmented into type I, type II, and type III.


On the basis of application, the dural arteriovenous fistulas treatment market is segmented into surgery, stereotactic radiosurgery, embolization, and others.


On the basis of end user, the dural arteriovenous fistulas treatment market is segmented into hospitals & clinics, ambulatory surgical centers, and others. 


Regional Analysis


The Americas dominates the dural arteriovenous fistulas treatment market owing to developing  technology, increasing cases of brain injury, rising prevalence of neurological disorders, growing healthcare spending, and increasing government support for research & development. Furthermore, increasing R&D activities and the presence of major companies have fuelled the growth of the market in this region.


Europe holds the second position in the dural arteriovenous fistulas treatment market. It is expected that the government support for research & development and availability of funds for research may drive the market in European region over the review period.


Asia Pacific is the fastest growing dural arteriovenous fistulas treatment market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing new opportunities in countries such as China, India, Japan, and South Korea projected to emerge as the fastest growing market across the globe. Furthermore, increasing demand for the neurological treatment may lead to the use of advanced equipment, which, in turn, will increase the growth of the dural arteriovenous fistulas treatment market in the region.


On the other hand, the Middle East and Africa holds the least share of the market due to limited medical facilities, lack of funds for research and development, and poor political conditions, especially, in Africa.


Key Players


Some of key the players in the dural arteriovenous fistulas treatment market are BD (U.S.), Medtronic (U.S.), B. Braun Melsungen AG (Germany), Cook (U.S.), Teleflex Incorporated (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), NxStage Medical, Inc.(U.S.), and Poly Medicure Limited. 


Research Methodology
Dural Arteriovenous Fistulas Treatment Market-


Sources: Annual reports, Press release, White paper, and Company presentation


 



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: Significant Value
  CAGR   6.60%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   BD (U.S.), Medtronic (U.S.), B. Braun Melsungen AG (Germany), Cook (U.S.), Teleflex Incorporated (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), NxStage Medical, Inc.(U.S.), and Poly Medicure Limited
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of brain injury and neurological disorders
  • Increasing investment in biotechnology and pharmaceutical industries in R&D
  • Rising need for the better treatment methods


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Dural arteriovenous fistulae treatment market is projected to grow at approximately 6.60% CAGR during the assessment period (2022-2030).

    Increasing prevalence of brain injury & neurological disorders, rising per capita healthcare expenditure, and increasing investment in biotechnology & pharmaceutical industries.

    Higher cost and reported cases of side effects associated with these treatment procedures are major growth impeders for the global dural arteriovenous fistulae treatment market.

    North America holds the largest share in the global dural arteriovenous fistulae treatment market, followed by Europe and the Asia Pacific, respectively.

    BD (U.S.), B. Braun Melsungen AG (Germany), Medtronic (U.S.), Cook (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Teleflex Incorporated (U.S.), NxStage Medical, Inc.(U.S.), and Poly Medicure Limited, are some of the top players operating in the global dural arteriovenous fistulae treatment market.